CentralCharts: Supercharge your portfolio with groundbreaking tools.

Investigators rapidly activate sites, expand trial reach, and achieve real-time data oversight with a complete and affordable cloud-based research imaging platform. CARY, NC / ACCESSWIRE / May 8, 2024 / Yunu , creator of a first-of-kind clinical trial imaging workflow, reading, and data management platform, is extending the reach of investigator-initiated trials (IITs) into broader and more diverse communities while harmonizing trial data on its unified cloud-based platform. By leveraging the...

Kojamo plc Interim Report 1 January-31 March 2024 PR Newswire HELSINKI, May 8, 2024 Kojamo plc Stock Exchange Release, 8 May 2024 at 2.00 p.m. EEST HELSINKI , May 8, 2024 /PRNewswire/ -- Total revenue and net rental income increased, no significant value changes in the investment properties This is a summary of the January–March Interim Report, which is in its entirety attached to this release and can be downloaded from the company's website at www.kojamo.fi/investors . Unless otherwise...

Invitation to news conference: Kamux Corporation publishes its Interim Report for January-March on May 17, 2024 PR Newswire ESPOO, Finland, May 8, 2024 Kamux Corporation Press release 8.5.2024 at 14:00 ESPOO, Finland , May 8, 2024 /PRNewswire/ -- Kamux Corporation will publish its Interim Report for January–March 2024 on Friday, May 17, 2024 , at approximately 9:00 EET . The report will be available at www.kamux.com after publishing. News conference for investors, analysts and media will be...

Revenue for the first quarter of 2024 remained stable at $242.9 million, compared with $242.5 million in the first quarter of 2023. Adjusted EBITDA was $164.2 million, a 0.9% 1 year-over-year decrease on a comparable basis. Net loss for the first quarter of 2024 attributable to the Company was $5.4 million, compared with a net loss of $11.0 million in the first quarter of 2023. Operating Cash Flow increase of 57.3% year-over-year up to $65.6 million. Signed a 15-year PPA for a 100 MW solar +...

- ATH434-201 Trial on Track to Complete in November 2024 – - Top-Line Data Expected in January 2025 - MELBOURNE, Australia and SAN FRANCISCO, May 08, 2024 (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) (“Alterity” or “the Company”), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced that an independent Data Monitoring Committee (DMC) has completed its third review of trial data and recommended...

TULSA, Okla., May 08, 2024 (GLOBE NEWSWIRE) -- Ladybug Resource Group, Inc. (OTC PINK: LBRG), now operating under the brand name Ladybug NutraTech, is excited to announce the signing of a Letter of Intent for the acquisition of a leading e-commerce platform from Your Supplement Supply Store Ltd. This strategic move marks a significant milestone in Ladybug NutraTech's expansion and enhancement of its digital retail footprint. This e-commerce platform has been designed to serve a niche market...

FORM 8.5 (EPT/RI) PUBLIC DEALING DISCLOSURE BY AN EXEMPT PRINCIPAL TRADER WITH RECOGNISED INTERMEDIARY STATUS DEALING IN A CLIENT-SERVING CAPACITY Rule 8.5 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Name of exempt principal trader: Investec Bank plc (b) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Centaur Media plc (c) Name of the party to the offer with which exempt principal trader is...